Early postoperative anticoagulation after mechanical valve replacement: A Canadian survey

Journal of Heart Valve Disease

Volumn 15, Issue 4, 2006, Pages 581-587

  Kulik, Alexander ^a   Rubens, Fraser D ^a   Baird, Donna ^a   Wells, Philip S ^b   Kearon, Clive ^b   Mesana, Thierry G ^a   Lam, B Khanh ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; AORTA VALVE REPLACEMENT; ARTICLE; CANADA; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG DOSE REGIMEN; HEART VALVE REPLACEMENT; HUMAN; INFORMATION PROCESSING; MITRAL VALVE REPLACEMENT; POSTOPERATIVE CARE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; SURGEON; THROMBOEMBOLISM;

ANTICOAGULANTS; AORTIC VALVE; ASPIRIN; BIOPROSTHESIS; CANADA; DATA COLLECTION; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEART VALVES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; MITRAL VALVE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINES; QUESTIONNAIRES; THORACIC SURGERY; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 33746398021     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kulik A, Rubens FD, van Berkom J, et al. Early postoperative anticoagulation after mechanical valve replacement: A systematic review. Ann Thorac Surg 2006;81:770-781
2. Edmunds LH, Jr. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987;44:430-445
3. Bonow RO, Carabello B, de Leon AC, Jr., et al. Guidelines for the management of patients with valvular heart disease: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998;98:1949-1984
4. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 1986;8(6 Suppl.B):41B-56B
5. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. Circulation 1989;80:1501-1513
6. Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970;283:1302-1305
7. Butchart EG, Lewis PA, Bethel JA, Breckenridge IM. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve. Circulation 1991;84(5 Suppl.):III61-III69
8. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-1119
9. Douglas PS, Hirshfeld JW, Jr., Edie RN, Harken AH, Stephenson LW, Edmunds LH, Jr. Clinical comparison of St. Jude and porcine aortic valve prostheses. Circulation 1985;72(3 Pt.2):II135-II139
10. Miller DC, Oyer PE, Stinson EB, et al. Ten to fifteen year reassessment of the performance characteristics of the Starr-Edwards Model 6120 mitral valve prosthesis. J Thorac Cardiovasc Surg 1983;85:1-20
11. Murphy DA, Levine FH, Buckley MJ, et al. Mechanical valves: A comparative analysis of the Starr-Edwards and Björk-Shiley prostheses. J Thorac Cardiovasc Surg 1983;86:746-752
12. Poller L. Therapeutic ranges in anticoagulant administration. Br Med J (Clin Res Ed) 1985;290:1683-1686
13. Barnhorst DA, Oxman HA, Connolly DC, et al. Isolated replacement of the mitral valve with the Starr-Edwards prosthesis. J Thorac Cardiovasc Surg 1976;71:230-237
14. Barnhorst DA, Oxman HA, Connolly DC, et al. Long-term follow-up of isolated replacement of the aortic or mitral valve with the Starr-Edwards prosthesis. Am J Cardiol 1975;35:228-233
15. Eybl E, Grimm M, Grabenwoger M, Bock P, Muller MM, Wolner E. Endothelial cell lining of bioprosthetic heart valve materials. J Thorac Cardiovasc Surg 1992;104:763-769
16. McClung JA, Stein JH, Ambrose JA, Herman MV, Reed GE. Prosthetic heart valves: A review. Prog Cardiovasc Dis 1983;26:237-270
17. Muriithi EW, Belcher PR, Day SP, Menys VC, Wheatley DJ. Heparin-induced platelet dysfunction and cardiopulmonary bypass. Ann Thorac Surg 2000;69:1827-1832
18. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(1 Suppl.):108S-121S
19. Meurin P, Weber H, Renaud N, et al. Evolution of the postoperative pericardial effusion after day 15: The problem of the late tamponade. Chest 2004;125:2182-2187
20. Pepi M, Muratori M, Barbier P, et al. Pericardial effusion after cardiac surgery: Incidence, site, size, and haemodynamic consequences. Br Heart J 1994;72:327-331
21. Malouf JF, Alam S, Gharzeddine W, Stefadouros MA. The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery. Eur Heart J 1993;14:1451-1457
22. Glock YF, Herreros J, Tejeira FJ. [Late tamponade after heart surgery: A dreadful diagnostic pitfall]. Can J Surg 1983;26:287-291
23. Solem JO, Kugelberg J, Stahl E, Olin C. Late cardiac tamponade following open-heart surgery. Diagnosis and treatment. Scand J Thorac Cardiovasc Surg 1986;20:129-131
24. Mangi AA, Palacios IF, Torchiana DF. Catheter pericardiocentesis for delayed tamponade after cardiac valve operation. Ann Thorac Surg 2002;73:1479-1483
25. Wilhelm M, Carrel T, Jenni R, Turina M. [Incidence, clinical aspects and therapy of late pericardial tamponade following heart surgery]. Swiss Surg 1996:92-96
26. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17
27. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease - native and prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl.):457S-482S
28. Canadian Cardiovascular Society Consensus Conference: Surgical Management of Valvular Heart Disease 2004. Can J Cardiol 2004-20(Suppl.E):1E-120E
29. Kontny F, Dale J, Abildgaard U, Hegrenaes L, Lem P, Morstol T. Adverse effect of warfarin in acute myocardial infarction: Increased left ventricular thrombus formation in patients not treated with high-dose heparin. Eur Heart J 1993;14:1040-1043
30. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-1828
31. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: A prospective randomized clinical trial. Circulation 1985;72:1059-1063
32. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-641
33. Ageno W, Turpie AG, Steidl L, et al. Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. Am J Cardiol 2001;88:40-44
34. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude Medical prosthesis: A clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2000;35:739-746
35. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: A meta-analysis. J Am Coll Cardiol 2001;37:569-578
36. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: A meta-analysis. Am Heart J 1995;130(3 Pt.1):547-552
37. Ray JG, Turpie AG. Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for patients with mechanical heart valves. Can J Cardiol 1997;13:1162-1165